Navigation Links
Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer

Dr. Pollard Brings the Highest Level of Clinical Immunology Expertise

MCLEAN, Va. and BUDAPEST, Hungary, Feb. 1 /PRNewswire/ -- Genetic Immunity(R), a US/Hungarian clinical-stage biopharmaceutical company focused on the development and commercialization of its patented immunotherapeutic platform technology, announced that it has appointed Richard B. Pollard, M.D. as Chief Medical Officer.

Dr. Pollard has been a leader in HIV/AIDS research for more than twenty years; he cared for his first patient with AIDS in 1982, and continues to provide primary care for hundreds of patients with HIV and related conditions. Dr. Pollard has been involved in the development of new treatments for the HIV, herpes, and hepatitis viruses. His laboratory, one of the five immunology specialty laboratories supported by the AIDS Clinical Trials Group (ACTG), performs multiple assays to monitor immunologic changes to HIV and opportunistic viral pathogens.

In addition, Dr. Pollard is Professor of Internal Medicine and Microbiology and Chief of the Division of Infectious Diseases at the University of California, Davis Medical School in Sacramento, CA. He currently serves as the Principal Investigator of the Immunology Specialty Laboratory, Chair of the ACTG Laboratory Evaluation Subcommittee, and Principal Investigator of the California Research Center for the Biology of HIV in Minorities.

Dr. Pollard said, "I'm excited to join Genetic Immunity's scientifically strong team; I believe that this team has the depth to develop scalable in vivo immunotherapies from the research stage though clinical development in a number of indications. As someone who has spent a quarter century active in AIDS care, I'm excited to work on the DermaVir Patch product as it is one of the most innovative approaches to HIV treatment. As a researcher, I'm impressed that an exceptional clinical observation inspired a new immune therapy technology."

Julianna Lisziewicz, Ph.D., Co-Founder and CEO of Genetic Immunity, said, "We are delighted that Dr. Pollard has decided to join the Genetic Immunity team following on 10 years of collaboration. Dr. Pollard was a pioneer in the field of AIDS research and today is one of the key opinion-leaders in HIV/AIDS and infectious diseases. His position on our management team demonstrates his belief in the potential of our technology. His presence in Hungary brings the highest level of clinical immunology expertise to the country's emerging biopharmaceutical industry. Dr. Pollard's experience in clinical development makes him an ideal fit for our company and adds strength to what is already a robust team."

About Genetic Immunity(R)

Genetic Immunity is a US/Hungarian development stage company establishing leadership in next-generation biopharmaceuticals. The Company is leveraging its proprietary platform technology to create new markets for infectious diseases, cancer and allergy through the discovery, development and commercialization of topically administered immune therapies. These indications represent significant unmet medical need and potential for alternative treatment approaches. Genetic Immunity's lead product, the DermaVir Patch for the treatment of HIV/AIDS, was discovered by the Company's founders, and is in Phase II clinical development with the opportunity to be the first immune therapy approved for HIV-infected individuals.

About DermaVir Patch

The proprietary DermaVir Patch is a topically administered HIV immune therapy, which emerged from the clinical observations of Genetic Immunity's founders. Their examination of the "Berlin Patient" proved that induction of immune control of HIV replication is feasible in an infected patient. The Company has developed the DermaVir Patch to induce the immune system to kill HIV infected cells specifically and to make immune therapy accessible for the majority of HIV infected individuals, including children. The DermaVir Patch, currently in Phase II clinical trials, is comprised of two patented components: NanoComp and DermaPrep. NanoComp is an antigen composition platform that combines a disease-specific plasmid DNA with the Company's formulation technology. The unique DNA for the DermaVir Patch product encodes the majority of HIV antigens, allowing a broad immune response. DermaPrep is a topical administration device by which NanoComp is delivered specifically into the dendritic cells.


The Ruth Group


Sara Ephraim



Janine McCargo


SOURCE Genetic Immunity
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation
2. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
3. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
4. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
5. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
6. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
7. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
8. deCODE genetics Announces Third Quarter 2007 Financial Results
9. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
10. ZymoGenetics to Host Conference Call and Webcast on October 31, 2007 to Discuss Third Quarter Results
11. Response Genetics CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
Post Your Comments:
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):